None, D. R., None, D. J. P. R. & None, D. P. S. (2026). Comparative Evaluation Of Intratympanic Steroid Therapy And Systemic Corticosteroid Therapy In Management Of Sudden Sensorineural Hearing Loss. Journal of Contemporary Clinical Practice, 12(11), 432-439.
MLA
None, Dr. Rani, Dr. Julie P R and Dr. Preeti Shahapur . "Comparative Evaluation Of Intratympanic Steroid Therapy And Systemic Corticosteroid Therapy In Management Of Sudden Sensorineural Hearing Loss." Journal of Contemporary Clinical Practice 12.11 (2026): 432-439.
Chicago
None, Dr. Rani, Dr. Julie P R and Dr. Preeti Shahapur . "Comparative Evaluation Of Intratympanic Steroid Therapy And Systemic Corticosteroid Therapy In Management Of Sudden Sensorineural Hearing Loss." Journal of Contemporary Clinical Practice 12, no. 11 (2026): 432-439.
Harvard
None, D. R., None, D. J. P. R. and None, D. P. S. (2026) 'Comparative Evaluation Of Intratympanic Steroid Therapy And Systemic Corticosteroid Therapy In Management Of Sudden Sensorineural Hearing Loss' Journal of Contemporary Clinical Practice 12(11), pp. 432-439.
Vancouver
Dr. Rani DR, Dr. Julie P R DJPR, Dr. Preeti Shahapur DPS. Comparative Evaluation Of Intratympanic Steroid Therapy And Systemic Corticosteroid Therapy In Management Of Sudden Sensorineural Hearing Loss. Journal of Contemporary Clinical Practice. 2026 Nov;12(11):432-439.
Background: Sudden sensorineural hearing loss (SSNHL) is an otological emergency commonly managed with corticosteroids. This study compared the efficacy and safety of intratympanic and systemic corticosteroid therapy. Materials and Methods: This prospective comparative study included 100 patients with SSNHL, divided into Group I (intratympanic dexamethasone, n = 50) and Group II (oral prednisolone, n = 50). Hearing thresholds, recovery rates, and adverse effects were assessed over 12 weeks. Results: Baseline pure-tone averages were comparable between groups. At 12 weeks, mean hearing improvement was significantly greater in Group I (31.58 ± 12.46 dB) than Group II (24.60 ± 11.84 dB; p = 0.005). Complete recovery occurred in 36.00% and 24.00% of patients, respectively. Overall recovery rates were 84.00% and 70.00% (p = 0.096). Intratympanic therapy was associated with fewer systemic adverse effects. Conclusion: Intratympanic steroid therapy showed greater audiological improvement and fewer systemic complications, suggesting its potential as an alternative to systemic corticosteroids in SSNHL management.
Keywords
Sudden sensorineural hearing loss
Intratympanic steroids
Systemic corticosteroids
Hearing recovery
Pure-tone audiometry.
INTRODUCTION
Sudden sensorineural hearing loss (SSNHL) is an otological emergency characterized by rapid hearing impairment, typically defined as a sensorineural hearing loss of at least 30 decibels (dB) affecting three consecutive frequencies within 72 hours[1]. It is usually unilateral and may be accompanied by tinnitus, aural fullness, vertigo, or imbalance. SSNHL significantly affects communication, psychological well-being, and quality of life. Although spontaneous recovery may occur, delayed diagnosis and treatment can result in persistent hearing impairment, emphasizing the importance of early therapeutic intervention [2].The etiology of SSNHL remains unidentified in most cases, which are classified as idiopathic sudden sensorineural hearing loss (ISSNHL). Proposed mechanisms include viral infections, cochlear microvascular compromise, autoimmune inflammation, oxidative stress, and cochlear membrane disruption. These processes may damage cochlear hair cells and auditory neural structures, resulting in hearing impairment. Prognostic factors such as age, initial hearing loss severity, audiometric configuration, associated vertigo, treatment delay, and underlying comorbidities may influence hearing recovery [2,3].Corticosteroids are widely used in SSNHL management because of their anti-inflammatory, immunosuppressive, and membrane-stabilizing effects. Systemic corticosteroids, administered orally or intravenously, have traditionally been considered an initial treatment option. However, their effectiveness varies, and systemic administration may cause hyperglycemia, hypertension, gastrointestinal disturbances, sleep disturbances, and immunosuppression. These adverse effects are particularly concerning in patients with diabetes mellitus, cardiovascular diseases, and other systemic comorbidities [1,4].Intratympanic steroid therapy has emerged as an alternative treatment that delivers corticosteroids directly into the middle ear, allowing diffusion through the round window membrane into the inner ear. This approach provides high local drug concentrations while minimizing systemic exposure. Dexamethasone and methylprednisolone are commonly administered through this route[5]. Intratympanic steroids may be used as primary treatment, combined therapy, or salvage treatment following inadequate recovery with systemic corticosteroids. However, potential complications include transient otalgia, dizziness, middle ear infection, and tympanic membrane perforation [6,7].Several studies have compared intratympanic and systemic corticosteroid therapy in SSNHL management. Rauch et al. demonstrated that intratympanic methylprednisolone was noninferior to oral prednisone as initial treatment [3]. Systematic reviews and meta-analyses by Mirian and Ovesen, Yang et al., and Mirsalehi et al. reported generally comparable hearing recovery outcomes between these treatment approaches [8–10]. Furthermore, randomized trials and meta-analyses have demonstrated the potential benefits of intratympanic corticosteroids as salvage therapy in patients with incomplete hearing recovery following initial treatment [11,12].Despite these findings, uncertainty persists regarding the optimal corticosteroid administration route. Variations in steroid type, dosage, treatment initiation, administration frequency, baseline hearing loss, and follow-up duration may influence therapeutic outcomes. Additionally, individual patient characteristics and associated comorbidities must be considered when selecting treatment. Comparative evaluation is therefore necessary to determine the relative effectiveness and safety of these approaches. The present study aimed to compare intratympanic steroid therapy with systemic corticosteroid therapy in patients with SSNHL, focusing on audiological improvement, hearing recovery, and treatment-related complications.
MATERIALS AND METHODS
Study Design and Setting
This hospital-based, prospective, comparative study was designed to evaluate the efficacy of intratympanic steroid therapy versus systemic corticosteroid therapy in patients diagnosed with sudden sensorineural hearing loss (SSNHL). The study was conducted in the Department of Otorhinolaryngology at a tertiary care hospital.The study was conducted over a period of 18 months.
Study Population
The study included adult patients diagnosed with unilateral idiopathic sudden sensorineural hearing loss who presented to the Department of Otorhinolaryngology and fulfilled the eligibility criteria.
Sample Size
A total of 100 patients diagnosed with SSNHL were included and divided into two groups of 50 patients each:
• Group I (n = 50): Patients receiving intratympanic steroid therapy.
• Group II (n = 50): Patients receiving systemic corticosteroid therapy.
Inclusion Criteria
1. Patients aged 18 years and above.
2. Patients presenting with sudden sensorineural hearing loss of at least 30 dB involving three consecutive frequencies within 72 hours.
3. Patients presenting within 14 days of symptom onset.
4. Patients with unilateral idiopathic SSNHL confirmed by pure-tone audiometry.
5. Patients willing to participate and provide written informed consent.
Exclusion Criteria
1. Patients with conductive or mixed hearing loss.
2. Patients with previous history of chronic otitis media, tympanic membrane perforation, or middle ear surgery.
3. Patients with hearing loss attributable to acoustic trauma, ototoxic drugs, or identifiable retrocochlear pathology.
4. Patients with bilateral or recurrent SSNHL.
5. Patients with active middle ear infection.
6. Patients who had already received corticosteroid therapy for the current episode.
7. Patients unwilling to participate or complete follow-up.
Patient Evaluation
All patients underwent detailed history taking and comprehensive otorhinolaryngological examination. Clinical information included age, sex, affected ear, duration of hearing loss, associated tinnitus, vertigo, aural fullness, and relevant medical comorbidities. Otoscopic examination was performed to exclude middle ear pathology. Baseline audiological evaluation included pure-tone audiometry (PTA) to assess hearing thresholds and determine the severity and configuration of hearing loss. Additional investigations were performed when clinically indicated to exclude identifiable causes of SSNHL.
Treatment Protocol
Group I: Intratympanic Steroid Therapy
Patients in Group I received intratympanic dexamethasone injections under aseptic precautions. Following topical anesthesia, dexamethasone (4 mg/mL) was administered through the anteroinferior quadrant of the tympanic membrane using a fine-gauge needle. Approximately 0.3–0.5 mL of the drug was injected into the middle ear. Patients remained in the supine position with the treated ear facing upward for approximately 20–30 minutes and were advised to avoid swallowing and speaking during this period. Injections were administered twice weekly for two weeks, providing a total of four injections.
Group II: Systemic Corticosteroid Therapy
Patients in Group II received oral prednisolone at a dose of 1 mg/kg/day, up to a maximum of 60 mg daily, for seven days, followed by gradual tapering over the subsequent seven days. Patients were monitored for potential corticosteroid-related adverse effects, including hyperglycemia, hypertension, gastrointestinal disturbances, and other systemic complications.
Follow-up and Outcome Assessment
Patients were evaluated at baseline and subsequently at 2 weeks, 4 weeks, and 12 weeks following treatment initiation. Pure-tone audiometry was performed during follow-up to assess hearing improvement.The primary outcome was the change in pure-tone average hearing threshold from baseline to 12 weeks. Secondary outcomes included hearing recovery rates, improvement in associated symptoms, and treatment-related adverse effects. Hearing recovery was categorized according to predefined audiometric criteria, with complete recovery defined as a final PTA of 25 dB HL or better, partial recovery as an improvement of at least 15 dB without complete recovery, and no significant recovery as an improvement of less than 15 dB.
Statistical Analysis
Data were entered into Microsoft Excel and analyzed using SPSS.25 statistical software. Continuous variables were expressed as mean ± standard deviation, while categorical variables were presented as frequencies and percentages. The independent-samples t-test or Mann–Whitney U test was used to compare continuous variables between groups, depending on data distribution. The paired t-test or Wilcoxon signed-rank test was used to evaluate within-group changes in hearing thresholds. Categorical variables were compared using the Chi-square test or Fisher's exact test. A p-value of less than 0.05 was considered statistically significant.
RESULTS
The study included 100 patients, equally divided into Group I and Group II (n = 50 each). Demographic characteristics were comparable between the groups, with most patients belonging to the 31–50-year age range. Male predominance was observed in both groups (58.00% vs. 56.00%). No significant differences were found in age (p = 0.920) or sex distribution (p = 0.841) (Table 1 and Figure 1).Baseline clinical characteristics were comparable between the groups. Right-ear involvement was observed in 54.00% and 52.00% of patients, respectively. Tinnitus was the most common associated symptom (76.00% vs. 72.00%), followed by aural fullness and vertigo. Most patients initiated treatment within 4–7 days, and moderately severe hearing loss was the most frequent baseline category. No statistically significant differences were observed (p > 0.05) (Table 2).Mean baseline PTA thresholds were comparable between Group I and Group II (69.42 ± 15.36 vs. 68.86 ± 14.92 dB HL; p = 0.853). Both groups demonstrated progressive hearing improvement. At 12 weeks, Group I showed significantly better hearing thresholds than Group II (37.84 ± 13.96 vs. 44.26 ± 14.88 dB HL; p = 0.028), whereas differences at 2 and 4 weeks were not statistically significant (Table 3).Mean hearing improvement at 12 weeks was significantly greater in Group I (31.58 ± 12.46 dB) than Group II (24.60 ± 11.84 dB; p = 0.005). Complete recovery was achieved in 36.00% and 24.00% of patients, respectively. Overall recovery was higher in Group I (84.00% vs. 70.00%), although the difference was not statistically significant (p = 0.096) (Table 4).Regarding adverse effects, transient otalgia was significantly more frequent in Group I (16.00% vs. 0.00%; p = 0.006), whereas hyperglycemia was significantly higher in Group II (18.00% vs. 2.00%; p = 0.016). Other adverse effects, including dizziness, gastrointestinal discomfort, elevated blood pressure, and sleep disturbances, showed no statistically significant differences (Table 5 and Figure 2).Correlation analysis revealed significant negative associations of hearing improvement with age (Group I: r = −0.284; Group II: r = −0.312) and treatment delay (r = −0.426 and −0.381, respectively). Baseline PTA showed a significant positive correlation with hearing improvement in both groups (r = 0.348 and 0.296, respectively; all p < 0.05) (Table 6 and Figure 3).
Table 1. Comparison of Demographic Characteristics Between the Two Groups (N = 100)
Parameter Group I (n = 50) Group II (n = 50) p-value Statistical test
Age group (years) 0.920 Chi-square
18–30 10 (20.00%) 9 (18.00%)
31–40 12 (24.00%) 13 (26.00%)
41–50 14 (28.00%) 13 (26.00%)
51–60 9 (18.00%) 10 (20.00%)
>60 5 (10.00%) 5 (10.00%)
Sex 0.841 Chi-square
Male 29 (58.00%) 28 (56.00%)
Female 21 (42.00%) 22 (44.00%)
Table 2. Comparison of Baseline Clinical Characteristics Between the Two Groups (N = 100)
Clinical characteristic Group I (n = 50) Group II (n = 50) p-value Statistical test
Affected ear 0.841 Chi-square
Right 27 (54.00%) 26 (52.00%)
Left 23 (46.00%) 24 (48.00%)
Associated symptoms
Tinnitus 38 (76.00%) 36 (72.00%) 0.648 Chi-square
Vertigo 15 (30.00%) 17 (34.00%) 0.668 Chi-square
Aural fullness 24 (48.00%) 22 (44.00%) 0.688 Chi-square
Duration before treatment 0.810 Chi-square
≤3 days 18 (36.00%) 17 (34.00%)
4–7 days 21 (42.00%) 20 (40.00%)
8–14 days 11 (22.00%) 13 (26.00%)
Baseline hearing loss severity 0.970 Chi-square
Moderate (41–55 dB) 12 (24.00%) 11 (22.00%)
Moderately severe (56–70 dB) 19 (38.00%) 20 (40.00%)
Severe (71–90 dB) 14 (28.00%) 14 (28.00%)
Profound (>90 dB) 5 (10.00%) 5 (10.00%)
Table 3. Comparison of Pure-Tone Average Hearing Thresholds at Different Follow-up Intervals (N = 100)
Assessment interval Group I (n = 50), Mean ± SD (dB HL) Group II (n = 50), Mean ± SD (dB HL) p-value Statistical test
Baseline 69.42 ± 15.36 68.86 ± 14.92 0.853 Independent t-test
2 weeks 51.24 ± 15.18 54.76 ± 15.62 0.256 Independent t-test
4 weeks 43.68 ± 14.72 48.92 ± 15.14 0.082 Independent t-test
12 weeks 37.84 ± 13.96 44.26 ± 14.88 0.028 Independent t-test
Table 4. Comparison of Hearing Improvement and Recovery Outcomes at 12 Weeks (N = 100)
Parameter Group I (n = 50) Group II (n = 50) p-value Statistical test
Mean hearing improvement (dB), Mean ± SD 31.58 ± 12.46 24.60 ± 11.84 0.005 Independent t-test
Hearing recovery category 0.175 Chi-square
Complete recovery 18 (36.00%) 12 (24.00%)
Partial recovery 24 (48.00%) 23 (46.00%)
No significant recovery 8 (16.00%) 15 (30.00%)
Overall recovery (complete + partial) 42 (84.00%) 35 (70.00%) 0.096 Chi-square
Table 5. Comparison of Treatment-Related Adverse Effects Between the Two Groups (N = 100)
Adverse effect Group I (n = 50) Group II (n = 50) p-value Statistical test
Transient otalgia 8 (16.00%) 0 (0.00%) 0.006 Fisher's exact
Transient dizziness 5 (10.00%) 2 (4.00%) 0.436 Fisher's exact
Tympanic membrane perforation 1 (2.00%) 0 (0.00%) 1.000 Fisher's exact
Hyperglycemia 1 (2.00%) 9 (18.00%) 0.016 Fisher's exact
Gastrointestinal discomfort 1 (2.00%) 7 (14.00%) 0.059 Fisher's exact
Elevated blood pressure 0 (0.00%) 5 (10.00%) 0.056 Fisher's exact
Sleep disturbances 1 (2.00%) 6 (12.00%) 0.112 Fisher's exact
Table 6. Correlation Between Clinical Parameters and Hearing Improvement at 12 Weeks (N = 100)
Variables correlated Group Pearson's r p-value Statistical test
Age vs hearing improvement I −0.284 0.045 Pearson correlation
II −0.312 0.027
Duration before treatment vs hearing improvement I −0.426 0.002
II −0.381 0.006
Baseline PTA vs hearing improvement I 0.348 0.013
II 0.296 0.037
DISCUSSION
The present comparative study evaluated intratympanic steroid therapy (Group I) and systemic corticosteroid therapy (Group II) in 100 patients with sudden sensorineural hearing loss (SSNHL), with 50 patients in each group. The findings suggested greater audiological improvement following intratympanic therapy, with fewer systemic adverse effects.In the present study, the largest proportion of patients belonged to the 41–50-year age group in Group I (28.00%), while the 31–40-year and 41–50-year age groups each accounted for 26.00% in Group II. Male patients constituted 58.00% and 56.00%, respectively. Na et al. [13] compared 87 children and 707 adults with sudden deafness and reported recovery rates of 72.4% and 70.6%, respectively (p > 0.05), indicating no significant age-group difference in recovery.Tinnitus was the most common associated symptom in Group I (76.00%) and Group II (72.00%), followed by aural fullness (48.00% and 44.00%) and vertigo (30.00% and 34.00%). Moderately severe hearing loss was predominant (38.00% and 40.00%). Stachler et al. [14] emphasized early audiometric confirmation and timely evaluation of SSNHL. In the present study, 78.00% of Group I and 74.00% of Group II initiated treatment within seven days.Baseline PTA was comparable between Group I (69.42 ± 15.36 dB) and Group II (68.86 ± 14.92 dB). At 12 weeks, PTA improved to 37.84 ± 13.96 dB and 44.26 ± 14.88 dB, respectively (p = 0.028). Mean hearing improvement was greater in Group I (31.58 ± 12.46 dB) than Group II (24.60 ± 11.84 dB; p = 0.005).Filipo et al. [15] compared oral and intratympanic prednisolone therapy in patients with idiopathic SSNHL and found hearing improvement with both approaches, without a significant overall difference in mean PTA improvement. However, intratympanic therapy showed better outcomes in selected audiometric configurations. The present findings favoured intratympanic therapy.Complete recovery occurred in 36.00% of Group I compared with 24.00% of Group II, while overall recovery rates were 84.00% and 70.00%, respectively (p = 0.096). Alexander et al. [16], in a study involving 37 adults, reported superior hearing outcomes with intratympanic dexamethasone 24 mg/mL compared with 10 mg/mL. These findings highlight the possible influence of steroid concentration on hearing recovery. The present study used dexamethasone 4 mg/mL and evaluated differences between administration routes rather than concentrations.Age showed negative correlations with hearing improvement in Group I (r = −0.284) and Group II (r = −0.312). Treatment delay demonstrated stronger negative correlations (r = −0.426 and −0.381, respectively). Baseline PTA showed positive correlations with absolute hearing improvement (r = 0.348 and 0.296). Na et al. [13] reported significantly better recovery among patients with mild hearing loss than those with profound hearing loss (p < 0.05), supporting the prognostic importance of initial hearing severity.Intratympanic therapy was associated with transient otalgia (16.00%), dizziness (10.00%), and tympanic membrane perforation (2.00%). Systemic therapy showed higher frequencies of hyperglycemia (18.00%), gastrointestinal discomfort (14.00%), and elevated blood pressure (10.00%). Stachler et al. [14] emphasized individualized treatment selection and consideration of therapeutic risks, supporting the importance of balancing hearing recovery against treatment-related complications.
CONCLUSION
Intratympanic steroid therapy demonstrated greater mean hearing improvement (31.58 dB) compared with systemic corticosteroid therapy (24.60 dB) in patients with sudden sensorineural hearing loss.Although overall hearing recovery was higher with intratympanic therapy (84.00% versus 70.00%), the difference was not statistically significant. Intratympanic steroid therapy may be an effective alternative to systemic corticosteroids, particularly in patients at risk of systemic adverse effects.
LIMITATIONS
The study was limited by its relatively small sample size of 100 patients and short follow-up duration of 12 weeks, restricting assessment of long-term hearing outcomes. The single-center design and potential influence of baseline hearing severity, treatment delay, and individual patient characteristics may limit the generalizability of findings.
Adenoidectomy and Endoscopic Myringotomy with and without ventilation tube insertion for Treatment of Otitis Media with Effusion in 6-12 years old Children.